GlassScriptPhysician profile
Eliad T Culcea
NPI 1831172816
$19,142.02
in general payments reported to CMS, 2019-2025
49 companies · $3,749 in 2025
The $3,749 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,962 · 2020: $814 · 2021: $434 · 2022: $1,037 · 2023: $972 · 2024: $3,174 · 2025: $3,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,121 · Travel and Lodging: $2,577 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,120.85 |
| Travel and Lodging | $2,577.45 |
| Education | $196.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $8,802.27 | 2019-2020 | |
| Boston Scientific Corporation | $2,453.57 | 2019-2025 | Vercise, Bionic Navigator, General - Dbs |
| Abbvie INC. | $1,245.34 | 2022-2025 | Qulipta, Ubrelvy |
| Medtronic, INC. | $1,222.39 | 2024 | Percept PC Brainsense |
| Celgene Corporation | $666.27 | 2022-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $580.87 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $547.61 | 2019-2025 | Vumerity, Spinraza, Qalsody |
| Novartis Pharmaceuticals Corporation | $493.70 | 2019-2025 | |
| Abbott Laboratories | $233.78 | 2019-2025 | Infinity |
| Genentech USA, INC. | $224.51 | 2020-2025 | Evrysdi, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $185.94 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $179.82 | 2021-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $153.95 | 2023-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $148.45 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $146.00 | 2021-2025 | Crexont, Rytary |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $140.94 | 2019-2025 | Dysport |
| Ucb, INC. | $137.15 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Amgen INC. | $132.72 | 2019-2025 | Aimovig, Uplizna |
| Livanova USA, INC. | $130.46 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurocrine Biosciences, INC. | $119.87 | 2019-2025 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $118.52 | 2024 | Xeomin |
| Acadia Pharmaceuticals INC | $115.06 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $95.39 | 2021-2024 | |
| Neurelis, INC. | $86.21 | 2020-2025 | Valtoco |
| Lundbeck LLC | $67.61 | 2022-2025 | Rexulti, Vyepti |
| Grifols USA, LLC | $64.45 | 2022-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $57.02 | 2023-2025 | Hyqvia |
| Eisai INC. | $45.30 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $44.51 | 2021 | |
| Pfizer INC. | $44.23 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.37 | 2022 | |
| Adamas Pharmaceuticals, INC. | $40.31 | 2020-2021 | |
| Allergan, INC. | $40.20 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $40.19 | 2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $37.00 | 2024 | |
| Janssen Biotech, INC. | $32.50 | 2025 | |
| Tanabe Pharma America, INC. | $30.62 | 2022-2025 | Radicava |
| Neuronetics, INC. | $26.39 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.31 | 2025 | Nuedexta |
| Banner Life Sciences, LLC | $16.94 | 2022 | |
| Onmark, INC. | $16.85 | 2025 | |
| Medtronic USA, INC. | $14.35 | 2019 | |
| Owp Pharmaceuticals, INC. | $14.31 | 2025 | Subvenite |
| Astrazeneca Pharmaceuticals LP | $14.14 | 2024 | Wainua |
| Jazz Pharmaceuticals INC. | $13.90 | 2023 | Epidiolex |
| Catalyst Pharmaceuticals, INC. | $13.50 | 2025 | |
| Cycle Pharmaceuticals INC | $13.38 | 2024 | Tascenso Odt |
| Lilly USA, LLC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliad Culcea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.